Online treatment for depression in people with osteoarthritis: a randomised controlled trial

Not Applicable

Completed

• Conditions: Depression; Mental Health - Depression

• Registration Number: ACTRN12613001174774
• Lead Sponsor: St Vincent's Hospital

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2013-10-25
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 100

Inclusion Criteria

Diagnosis of current Major Depressive Disorder (MDD) based on the Mini International Neuropsychiatric Interview Version 5.0.0.

Diagnosis of symptomatic Osteoarthritis based upon radiographic criteria and pain on most days. The recruitment pathway ensures all potential participants (i.e., those who are informed about the study) meet this eligibility criterion.

Age 50+

Prepared to provide name, phone number and address, and to provide the name and address of a local general practitioner, and to provide informed consent.

English language skills equivalent to a School Certificate level.

Have access to a phone and a computer with regular Internet access and a printer.

Exclusion Criteria

Severe depression (PHQ-9 >23) and/ or current suicidality (PHQ-9 Q9=2 or 3).

If taking medication for anxiety or depression, has been taking the same dose for less than 1 month or intended to change the dose during the course of the program.

Currently receiving CBT for depression or completed an iCBT or CBT program for depression in the past 6 months or intention to commence CBT for depression.

Psychosis, bipolar disorder, substance abuse or dependence.

Taking antipsychotics or benzodiazepines.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Reductions in the Patient Health Questionnaire – 9-Item (PHQ-9)[Baseline, mid-treatment (week 4), 1 week post-treatment (week 11), and 3 months after post-treatment (week 24).];Reductions in psychological distress according to the Kessler-10 (K10).[Baseline, mid-treatment (week 4), 1 week post-treatment (week 11), and 3 months after post-treatment (week 24).]

Secondary Outcome Measures

Name	Time	Method
Reductions in the SF-12 – a 12 item validated measure of functional health and wellbeing.[Baseline, 1 week post-treatment (week 11), and 3 months after post-treatment (week 24).];Reductions in the Generalized Anxiety Disorder 7-Item (GAD-7).[Baseline, 1 week post-treatment (week 11), and 3 months after post-treatment (week 24).];Change in the Pain Catastrophising Scale – (PCS)[Baseline, 1 week post-treatment (week 11), and 3 months after post-treatment (week 24).];Change in the Arthritis Self Efficacy Scale.[Baseline, 1 week post-treatment (week 11), and 3 months after post-treatment (week 24).];Change in the Western Ontario and McMaster (WOMAC) Osteoarthritis.[Baseline, 1 week post-treatment (week 11), and 3 months after post-treatment (week 24).];PainDetect Questionnaire (PD-Q). [The PD-Q will be used to assess the relationship between depressive symptoms severity and neuropathic pain measured at baseline. ];Treatment Credibility/Expectancy Questionnaire (CEQ).[Measured at baseline.]